Schroders Capital Global Innovation Trust PLC - London-based investment trust with a diversified portfolio of global private and public equity companies - Receives $5.8 million distribution related to the first milestone of the Kymab sale to Sanofi SA. In April 2021, Schroders Capital Global Innovation completed the sale of its shares in Kymab to Sanofi for initial proceeds of $87 million. Company says: ‘At that time, the company explained there was the potential for additional contingent payments of up to $27 million subject to the achievement of various development and regulatory milestones. This announced payment reflects the first milestone event, with the potential for $21 million of further contingent payments in the future.’

Current stock price: 13.20 pence, up 0.4%

12-month change: down 7.8%

Copyright 2024 Alliance News Ltd. All Rights Reserved.